Product
MID Prism (AI-Powered Diagnostics)
High-precision detection of antibody changes, capable of identifying Mycoplasma infections even in asymptomatic patients.
Author
CEO & Founder at M Bio Technology Inc.
TOKYO, Japan
About
M Bio Technology Inc.: Unlocking the Frontier of Neuroimmune Medicine
M Bio Technology is a Tokyo-based biotechnology pioneer dedicated to tackling one of the most overlooked global health threats: Mycoplasma-driven neuroimmune diseases. While Mycoplasma is often associated with pediatric pneumonia—linked to up to 50% of cases—its role as a trigger for severe autoimmune and neurological conditions remains largely undiagnosed and untreated.
We are building a Japan-originated global clinical trial hub to transform how the world diagnoses, treats, and prevents these conditions, which include acute disseminated encephalomyelitis (ADEM), multiple sclerosis (MS), and various psychiatric disorders.
CL 4: Quantum
HORIZON-CL4-2026-04-DIGITAL-EMERGING-11: Grand Challenge on Quantum Sensors for Inertial Navigation
CL 4: Other emerging technologies
HORIZON-CL4-2027-04-DIGITAL-EMERGING-10: Horizon scanning and foresight in future enabling digital technologies (CSA)
CL 4: Virtual Worlds – Web 4.0 (Partnership)
HORIZON-CL4-2026-04-HUMAN-01: Developing and demonstrating core technologies for Virtual Worlds and Web 4.0 (IA) (Virtual worlds Partnership)
CL 6: Innovating for sustainable bio-based systems, biotechnology and the bioeconomy
HORIZON-CL6-2026-01-CIRCBIO-07: Advancing the European bio-based innovation enabled by biotechnology and biomanufacturing conceptsHORIZON-CL6-2027-01-CIRCBIO-08: Biotechnology application for CCU
CL4: Sustainable Advanced Materials, Raw Materials and Chemicals
HORIZON-CL4-2027-01-MATERIALS-PRODUCTION-22: Innovative advanced materials and new production processes – reducing dependencies on Critical and Strategic Raw Materials (IA) (Innovative Advanced Materials for the EU and Processes4Planet partnerships)HORIZON-CL4-2026-01-MATERIALS-PRODUCTION-24: Cooperation on innovative advanced materials with Japan (CSA)
CL 4: Technology infrastructure, knowledge valorisation and support for scaleups and startups
HORIZON-CL4-2027-01-MATERIALS-PRODUCTION-42: Unlocking the potential of academic intellectual assets for industry, SMEs and startups (CSA)HORIZON-CL4-2027-01-MATERIALS-PRODUCTION-61: Fast Track to Research and Innovation for breakthroughs in industrial technologies (Research and Innovation Action)
CL 4: AI for manufacturing and energy-intensive industries
HORIZON-CL4-2027-02-DIGITAL-EMERGING-52: New approaches for Human/AI collaboration for the workforce of the future (RIA) (Made in Europe and AI, Data and Robotics partnerships)
Representatives
Remote
Remote
CEO & Founder
M Bio Technology Inc.
Marketplace (5)
Product
MID Modality (Vaccine Innovation)
The world’s first synthetic glycolipid antigen-based vaccines, designed for high purity and global scalability.
AuthorCEO & Founder at M Bio Technology Inc.
TOKYO, Japan
Product
MID Navigator (Digital Health/Clinical Trials)
A PMDA-compliant trial orchestration tool and digital care system to guide physicians with real-time insights.
AuthorCEO & Founder at M Bio Technology Inc.
TOKYO, Japan
Project cooperation
Ongoing negotiations with a Global Tier-1 Vaccine Pharma and established partnerships with top-tier European CDMOs for GMP manufacturing.
AuthorCEO & Founder at M Bio Technology Inc.
TOKYO, Japan
Expertise
Deep domain knowledge in rare neuroimmune diseases like ADEM and Multiple Sclerosis (MS) triggered by infections.
AuthorCEO & Founder at M Bio Technology Inc.
TOKYO, Japan